<DOC>
	<DOCNO>NCT02689505</DOCNO>
	<brief_summary>This Phase I , multi-centre , non-randomized , uncontrolled , open-label , dose escalate study BI 836880 administer intravenously week . The eligible patient population patient advance solid tumor . The primary objective trial determine maximum tolerate dose ( MTD ) recommend Phase II dose BI 836880 patient solid tumor . Preliminary safety data evaluate secondary objective . Subsequently , pharmacokinetic profile , pharmacodynamic change circulate biomarkers Dynamic Contrast-Enhanced Magnetic Resonance Imaging ( DCE-MRI ) , anti-tumor activity immunogenicity BI 836880 explore total 40 patient advance solid tumor . Dose escalation guide Bayesian logistic regression model dose control ( EWOC ) use least 2 patient per dose cohort . Safety criterion follow , include adverse event accord Common Terminology Criteria ( CTCAE version 4.03 ) , incidence dose limit toxicity , physical examination , vital sign , safety laboratory parameter Eastern Cooperative Oncology Group ( ECOG ) .</brief_summary>
	<brief_title>Weekly BI 836880 Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion criterion : 1 Age &gt; =18 year 2 . Histologically confirm malignancy locally advance metastatic solid tumor , either refractory standard therapy disease standard therapy reliably effective e.g . patient tolerate contraindication otherwise available standard therapy . 3 . ECOG performance status &lt; = 2 4 . Adequate hepatic , renal bone marrow function define follow criterion : 1 . Total bilirubin within normal limit ( &lt; = 1.5x upper limit normal ( ULN ) patient Gilberts syndrome ) 2 . Alanine amino transferase ( ALT ) aspartate amino transferase ( AST ) &lt; = 1.5x ULN ( &lt; 5x upper limit normal ( ULN ) patient know liver metastasis ) 3 . Serum creatinine &lt; 1.5x ULN 4. International normalize Ratio ( INR ) 0.81.2 partial thromboplastin time ( PTT ) &lt; 1.5x ULN 5 . Absolute neutrophil count ( ANC ) &gt; 1.5 109/L 6 . Platelet count &gt; 100x109/ L. 7 . Haemoglobin &gt; 10 g/dl ( without transfusion within previous week ) 5 . Signed date write informed consent . 6 . Life expectancy &gt; = 3 month opinion investigator 7 . Recovery reversible adverse event previous anticancer therapy baseline CTCAE grade1 , except alopecia ( grade ) , sensory peripheral neuropathy CTCAE grade &lt; = 2 consider investigator clinically significant . 8 . Male female patient . Women childbearing potential* must ready able use highly effective method birth control per International Conference Harmonisation [ ICH M3 ( R2 ) ] combination male condom `` double barrier '' , trial least 6 month end treatment BI 836880 , result low failure rate le 1 % per year use consistently correctly . A list contraception method meet criterion provide patient information . Male patient must always use condom sexually active trial least 6 month end treatment BI 836880 . *Women childbearing potential define : Any female experience menarche meet criterion `` woman childbearing potential '' describe . Women childbearing potential define : Women postmenopausal ( 12 month menses without alternative medical cause ) permanently sterilize ( e.g. , tubal occlusion , hysterectomy , bilateral oophorectomy bilateral salpingectomy ) . Exclusion criterion : 1 . Known hypersensitivity trial drug excipients risk allergic anaphylactic reaction study drug accord investigator judgement ( e.g . patient history anaphylactic reaction autoimmune disease control nonsteroidal antiinflammatory drug ( NSAIDS ) , inhaled corticosteroid , equivalent &lt; 10 mg/day prednisone ) 2 . Current prior treatment systemic anticancer therapy either within 28 day minimum 5 halflives , whichever short start study treatment . 3 . Serious concomitant disease ( base investigator judgement ) , especially affect compliance trial requirement consider relevant evaluation endpoint trial drug , neurologic , psychiatric , infectious disease active ulcer ( gastrointestinal tract , skin ) laboratory abnormality may increase risk associate trial participation trial drug administration , judgment investigator would make patient inappropriate entry trial . 4 . Major injury and/or surgery ( judge investigator ) bone fracture within 4 week start study treatment , plan surgical procedure trial period . 5 . Patients personal family history QT prolongation and/or long QT syndrome , prolong QT interval correct heart rate accord Fridericia 's formula ( QTcF ) baseline ( &gt; 470 m ) . QTcF calculate Investigator mean 3 ECGs take screening . 6 . Significant cardiovascular/ cerebrovascular disease ( i.e uncontrolled hypertension , unstable angina , history infarction within past 6 month , congestive heart failure &gt; New York heart association ( NYHA II ) . Uncontrolled hypertension define : blood pressure test relaxed condition &gt; = 140 mmHg , systolic &gt; 90 mmHg diastolic ( without medication ) , measure accord Section 5.3.2 Appendix 10.2 . 7 . History severe haemorrhagic thromboembolic event past 12 month ( exclude central venous catheter thrombosis peripheral deep vein thrombosis ) . 8 . Known inherited predisposition bleed thrombosis opinion investigator . 9 . Patient brain metastasis symptomatic and/or require therapy . 10 . Patients require fulldose anticoagulation ( accord local guideline ) . No vitamin K antagonist anticoagulation allow ; lowmolecularweight heparin ( LMWH ) allow prevention curative treatment . 11 . Use alcohol drug incompatible patient participation study investigator opinion 12 . Patient unable unwilling comply protocol 13 . Women pregnant , nursing , plan become pregnant trial 14 . Previous enrolment trial</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>